Welcome to our dedicated page for Intelligent Bio Solutions news (Ticker: INBS), a resource for investors and traders seeking the latest updates and insights on Intelligent Bio Solutions stock.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company focused on intelligent, rapid, non-invasive testing solutions, with a primary emphasis on its Intelligent Fingerprinting Drug Screening System. The INBS news feed on Stock Titan aggregates company announcements, press releases and related coverage so readers can follow developments around its fingerprint-based drug screening platform, partnerships and capital markets activity.
Recent news highlights include record fiscal 2026 first quarter revenue driven by consumable cartridge sales, the addition of dozens of new customer accounts across more than 24 countries, and large deployments with organizations in sectors such as industrial services and public transport. Updates also cover the company’s razor–razor-blade business model, where installed readers support recurring cartridge revenue, and its efforts to expand adoption in safety-critical industries like construction, manufacturing and engineering, transport and logistics, mining and government administration.
INBS news items frequently address strategic partnerships and manufacturing, such as the collaboration with Syrma Johari MedTech Ltd to scale production of the Intelligent Fingerprinting Drug Screening Reader, and the alliance with Vlepis Pty Ltd to explore wearable patch technologies and consumer health monitoring. Additional coverage includes the distribution agreement for the SmarTest Patch, a 7–10 day continuous drug monitoring solution, and updates on regulatory pathways, including anticipated FDA 510(k) submissions.
Investors can also track capital structure and listing-related developments, including reverse stock split decisions, Nasdaq bid price deficiency notices and private placement financings with institutional investors. By reviewing the INBS news stream, readers gain context on how Intelligent Bio Solutions is executing its commercial strategy, expanding its customer base, managing manufacturing partnerships and addressing regulatory and listing requirements over time. Bookmark this page to quickly access the latest official communications and market-moving updates related to INBS.
Intelligent Bio Solutions (INBS) has expanded its fingerprint drug testing presence in Spain and Andorra through a strategic partnership with Detecto, a division of MTB Distribuciones Tecnologicas SL. The collaboration targets the Spanish drug testing market, projected to reach $448 million by 2030.
Major clients including Metro Barcelona and a large Rio Tinto-based mine currently require 1,000 drug testing cartridges monthly. The system has gained acceptance due to its non-invasive nature, easy collection process, and reduced maintenance costs through yearly calibration.
Detecto is expanding its focus to include law enforcement, rehabilitation, and maritime sectors, while seeing growth opportunities in ports, mining, and transportation. The partnership aims to leverage both companies' strengths to expand fingerprint sweat-based drug testing across various sectors.
Intelligent Bio Solutions (INBS) has secured its sixth U.S. patent (No. 12259385) for its Intelligent Fingerprinting Drug Screening Cartridge technology. The patent specifically protects the proprietary lateral flow test strip inside the screening cartridge, ensuring protection for all current and future screening products under U.S. intellectual property law.
The company's innovative technology uses fingerprint sweat analysis to detect common drugs of abuse, offering a non-invasive solution for safety-sensitive industries. This development strengthens INBS's competitive position as it prepares to enter the multi-billion dollar U.S. market in 2025.
Following its FDA 510(k) submission in December 2024, INBS is positioning itself to capitalize on the growing global drug screening market. The patent adds to the company's existing IP portfolio, which includes patents for their Sample Collection Cartridge, cartridge housing, and buffer clip design.
Intelligent Bio Solutions (NASDAQ: INBS) provided an update on its FDA clearance process for the Intelligent Fingerprint Drug Screening System, confirming its planned 2025 U.S. launch remains on track. The company submitted its 510(k) premarket notification on December 18, 2024, for its opiate test system, classified as a Class II device.
The submission included performance data showing 94.1% accuracy and Pharmacokinetic (PK) study results demonstrating fingerprint sweat's reliability for drug detection. The FDA has issued an Additional Information (AI) request, temporarily pausing the 90-day review period. While FDA clearance typically takes 3-6 months, the process may extend if additional data is required.
The system is currently operational in 19 countries with over 400 accounts globally. INBS plans to pursue FDA clearance for additional drug classes on its panel while preparing for entry into the U.S. market.
Intelligent Bio Solutions (INBS) announced the anticipated receipt of its sixth U.S. patent, strengthening protection for its lateral flow technology used in the Intelligent Fingerprinting Drug Testing Solution. The patent will safeguard the company's unique fingerprint sweat-based drug screening technology.
The expected patent grant comes as INBS advances its U.S. market entry strategy planned for 2025. The company's proprietary non-invasive drug testing technology addresses growing demand for workplace safety and compliance solutions. INBS has recently submitted an FDA 510(k) application and aims to expand its global market presence with this innovative sweat-based approach to drug screening.
Intelligent Bio Solutions (Nasdaq: INBS), a medical technology company focused on intelligent, rapid, non-invasive testing solutions, has announced its participation in the upcoming iAccess Alpha Virtual Best Ideas Spring Conference 2025.
The conference is scheduled for March 25-26, 2025, with INBS management's presentation set for Tuesday, March 25th at 11:00 a.m. ET. The presentation will be accessible via webcast. Additionally, the company will conduct one-on-one meetings during the conference, which interested parties can schedule through iAccess representatives or by contacting KCSA Strategic Communications.
Intelligent Bio Solutions (Nasdaq: INBS) has completed its previously announced underwritten public offering, raising approximately $3.0 million in gross proceeds. The offering consisted of 1,500,000 shares of common stock priced at $2.00 per share, including the full exercise of the underwriter's option to purchase an additional 195,652 shares.
Ladenburg Thalmann & Co. Inc. served as the sole bookrunning manager for the offering, which was conducted under a shelf registration statement previously filed and declared effective by the SEC. The final prospectus supplement and accompanying prospectus are available on the SEC's website.
Intelligent Bio Solutions (Nasdaq: INBS) has announced the pricing of its public offering of 1,304,348 shares of common stock at $2.00 per share, aiming to raise approximately $2.6 million in gross proceeds before deducting underwriting costs and expenses.
Ladenburg Thalmann & Co. Inc. is serving as the sole bookrunning manager for the offering. The company has granted the underwriter a 45-day option to purchase up to an additional 195,652 shares at the public offering price less underwriting discounts. The offering is expected to close around February 21, 2025.
The net proceeds will be used for working capital and general corporate purposes. The offering is being made through a shelf registration statement filed with the SEC on April 8, 2022, and declared effective on April 20, 2022.
Intelligent Bio Solutions (Nasdaq: INBS), a medical technology company focused on rapid, non-invasive testing solutions, has announced plans for an underwritten public offering of common stock shares. The offering will be managed by Ladenburg Thalmann & Co. Inc. as the sole bookrunning manager.
The offering is being conducted under a shelf registration statement filed with the SEC on April 8, 2022, and declared effective on April 20, 2022. A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC. The completion, size, and terms of the offering are subject to market conditions, with no guarantees of successful execution.
Intelligent Bio Solutions (NASDAQ: INBS) reported its fiscal Q2 2025 results, highlighting a 32.6% increase in gross profit and an 11-point rise in gross profit margin to 38.5%, driven by higher-margin cartridge sales. The company submitted its FDA 510(k) application in December 2024 and remains on track for U.S. market expansion in 2025.
Key financial metrics include Q2 revenue of $0.61 million, cash and equivalents of $2.24 million, and shareholders' equity of $4.20 million. The company secured 19 new accounts during the quarter, expanding its presence to over 400 active customers across 19 countries. However, revenue from sales decreased by $156,569 compared to the same quarter last year, and net loss increased to $2.25 million.
The company formed strategic partnerships with B2i Digital for investor marketing and Spirit Group for distribution in the Asia-Pacific region, while successfully completing method comparison and pharmacokinetic studies for its Intelligent Fingerprinting Drug Screening System.
Intelligent Bio Solutions (INBS) reported significant achievements in 2024 and outlined its 2025 U.S. expansion strategy. The company completed its FDA 510(k) pre-market notification in December 2024 for its Intelligent Fingerprinting Drug Testing Solution. Key financial highlights include 148% year-over-year revenue growth in fiscal 2024 and preliminary Q2 FY2024 revenue of $0.61 million, with improved gross profit margins reaching 38.5%.
The company currently serves over 400 accounts across 19 countries, reaching an estimated 1.4 million employees. Recent studies demonstrated approximately 94% accuracy in their drug testing system, with fingerprint sweat proving to be a reliable testing matrix. INBS is targeting the U.S. drug screening market, which represents 28% of the global market, with the total addressable market projected to reach $15 billion in the next six years.